Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema.

Authors :: Ercalik NY
Imamoglu S
Kumral ET
Yenerel NM
Bardak H
Bardak Y
Source :: Arquivos brasileiros de oftalmologia [Arq Bras Oftalmol] 2016 Nov-Dec; Vol. 79 (6), pp. 373-375.
Publication Year :: 2016
Abstract: Purpose:: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME).<br />Methods:: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated.<br />Results:: In the study group, although the CMT was significantly reduced following the first injection (p<0.001), BCVA did not improve significantly (p=0.296). However, after the first injection, the control group exhibited both a significant decrease in CMT (p<0.001) and improvement in BCVA (p<0.001). However, the improvement in BCVA in the control group was not significantly different from the outcome of the study group.<br />Conclusions:: We observed a negative short-term influence of the ERM on IVR treatment for DME.

Subjects :: Aged
Case-Control Studies
Female
Humans
Intravitreal Injections
Male
Middle Aged
Retrospective Studies
Angiogenesis Inhibitors administration & dosage
Diabetic Retinopathy drug therapy
Epiretinal Membrane physiopathology
Macular Edema drug therapy
Ranibizumab administration & dosage
Visual Acuity physiology

Full Text Access

Tools